Author: Michelle Sommer
Heidelberg, Germany, 1 September 2026 – BioMed X, a leading innovation engine for pharma, today announced the relocation of its global headquarters to LAB22 at Heidelberg Innovation Park (hip), together with the launch of a global partnership with BioLabs, a leading provider of shared laboratory infrastructure for life science innovators. Over the coming months, BioMed X will relocate its global headquarters […]
read more
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Ladenburg, Germany, 28 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma […]
read more
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Ladenburg, Germany, 26 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the […]
read more
Cells Have an Early-Warning System for Stress in Mitochondria
Internal protective mechanism responds to the very first signs of mitochondrial dysfunction Mitochondria – the powerhouses of the cell – have their own monitoring system that detects oxidative stress at a very early stage. It activates protective mechanisms even before the damage caused by this stress can spread to the rest of the cell. This […]
read more
From Cardiovascular Research to a Biotech Company: REVIER Therapeutics Launches with €6 Million
Heidelberg-based biotech company REVIER Therapeutics has officially launched. The company, which emerged from research conducted at the German Centre for Cardiovascular Research (DZHK) and Heidelberg University, is developing a novel therapeutic approach for cardiometabolic diseases. REVIER has raised €6 million in seed funding to advance its development programs. At the heart of REVIER’s approach are […]
read more
13.2 million euros for new immunotherapies against Ewing sarcomas in children and adolescents
The European research project THEODORA is launching during “Gold September”, the international childhood cancer awareness month. Researchers at the Heidelberg Medical Faculty of Heidelberg University, drawing on their expertise in clinical research and precision oncology at Hopp Children’s Cancer Center Heidelberg (KiTZ), are collaborating with Institut Curie in Paris, Prinses Máxima Centrum in Utrecht, and […]
read more
Light-Based 3D Printing: Innovative “Ink” Enables a Closed-Loop Material Cycle
Heidelberg research team develops a polymer material that can be broken down into its individual components and reused Polymers used for light-based 3D printing are very stable due to their chemical structure, but they are typically hard to recycle. A research team led by Prof. Dr. Eva Blasco, a researcher at the Institute for Molecular […]
read more
Colon Cancer: How Highly Aggressive Tumors Evade the Immune System
Researchers from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have identified a previously unknown mechanism by which a particularly aggressive form of colon cancer evades the immune system. The findings show that the activation of a key signaling pathway helps cancer cells suppress the immune system, thereby promoting the development […]
read more
Immune Cells in Bone Marrow Cancer: Limited Defense Readiness
A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, […]
read more
